Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
973.2 USD | -1.20% | -1.43% | +10.80% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.11 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.80% | 106B | B+ | ||
+9.83% | 118B | B+ | ||
-10.84% | 23.4B | B+ | ||
-1.69% | 22.1B | B | ||
-10.23% | 18.34B | A- | ||
-41.92% | 16.59B | A- | ||
-15.11% | 15.97B | B | ||
+6.62% | 14.03B | C+ | ||
+17.53% | 11.67B | C+ | ||
-30.73% | 7.55B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- REGN Stock
- Ratings Regeneron Pharmaceuticals, Inc.